Additionally, they highlight the importance of GLUT1 as a valuable biomarker in GBM diagnostics and therapy, emphasizing its role in identifying tumor characteristics, guiding treatment decisions, and monitoring therapeutic responses. This evidence concerns the gene SLC2A1 and neoplasm.